AbbVie Submits Regulatory Applications to FDA and EMA for Up

/PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that it has submitted applications for a new indication to the U.S. Food and Drug Administration (FDA) and...

Related Keywords

Ohio , United States , Liz Shea , Sara Sanders , Neil Gallagher , Instagram , Linkedin , Twitter , Drug Administration , Exchange Commission , Allergan , European Medicines Agency , Facebook , Abbvie Inc , Abbvie Deutschland Gmbh Co , Crohn Colitis Foundation Of America , Disease Activity Index , Important Safety , Mississippi River , Full Prescribing Information , Allergan Aesthetics , Private Securities Litigation Reform Act , Quarterly Reports , Participants With Moderately , Severely Active Crohn , Disease Who Have Inadequately Responded , Are Intolerant , Long Term Extension Study , Participants With Crohn , Disease Who Completed , Vie Deutschland Gmbh , Psoriatic Arthritis , Inadequate Response , Week Data , Randomized Controlled Phase , Inflammatory Bowel , Colitis Foundation , North Chicago , Evaluate Efficacy , Adult Participants With Axial Spondyloarthritis , Maintenance Therapy , Subjects With Moderately , Severely Active Ulcerative , Compare Safety , Adult Participants With Moderate , Severe Atopic Dermatitis , Severely Active Ulcerative Colitis , Participants With Giant Cell Arteritis , Subjects With Takayasu Arteritis , Abbvie ,